secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0000950170-24-020616
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VK2735 Phase 2 meets endpoints: up to 14.7% weight loss, 88% achieve ≥10% loss
------------------------------------------------------------------------------

- Primary and all secondary endpoints met; up to 14.7% mean weight loss from baseline (13.1% placebo-adjusted) after 13 weeks.
- Up to 88% of VK2735-treated patients achieved ≥10% weight loss vs 4% for placebo.
- No weight loss plateau observed; reductions progressive through week 13.
- Well-tolerated: 92% of drug-related TEAEs mild/moderate; low discontinuation (13% vs 14% placebo).
- Company plans FDA meeting to discuss next steps; oral formulation data expected this quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024020616/0000950170-24-020616-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024020616/vktx-20240227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-020616

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer